KRAS and pancreatic neoplasm: Molecular evidences support the master role of oncogenic KRAS disrupting the metabolic homeostasis via alteration of glucose uptake, glycolytic flux, and glutamine usage in colon and pancreatic tumors that often display very high resilience to chemotherapy [3].